2022 the Japanese Society of Medical Oncology Annual Meeting

Presentation information

Print

Mini-Oral Session

[MO38] Mini-Oral Session 38　Cross-sectional Program 4（PhaseⅠ trial and Precision medicine）
【E】

Sat. Feb 19, 2022 9:10 AM - 10:00 AM Room 7 (Room E, 1F, Kyoto International Conference Center)

Chair：Takafumi Koyama（Department of Experimental Therapeutics, National Cancer Center Hospital），Akira Hirasawa（Department of Clinical Genomic Medicine, Graduate School oF Medicine, Dentistry and Pharmaceutical Sciences, Okayama University）

[MO38-2] Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors

○Kentaro Yamazaki1, Takayuki Yoshino2, Kazunori Honda3, Yasutoshi Kuboki2, Takeshi Kawakami1, Seiichiro Mitani3, Yoshiaki Nakamura2, Hiroya Taniguchi3, Hideaki Bando2, Tomoyuki Tanaka4, Keisuke Tada4, Nathalie Fagniez5, Kei Muro3 (1.Shizuoka Cancer Center, Shizuoka, Japan, 2.National Cancer Center Hospital East, Chiba, Japan, 3.Aichi Cancer Center Hospital, Aichi, Japan, 4.Sanofi, Tokyo, Japan, 5.Sanofi, Chilly-Mazarin, France)

Abstract password authentication.
The password can be found on page 27 of the program book.

Password